BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.95 USD
-0.19 (-2.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.96 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
BioCryst Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BCRX 7.95 -0.19(-2.33%)
Will BCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
Other News for BCRX
BioCryst Pharmaceuticals Q2 2025 Earnings Preview
Earnings Outlook For BioCryst Pharma
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO
BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock news
BioCryst (BCRX) Announces Leadership Transition Plan